Global 23-Valent Pneumococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.

According to APO Research, The global 23-Valent Pneumococcal Polysaccharide Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for 23-Valent Pneumococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for 23-Valent Pneumococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for 23-Valent Pneumococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for 23-Valent Pneumococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine include MSD, Sanofipasteur and CDIBP, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for 23-Valent Pneumococcal Polysaccharide Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of 23-Valent Pneumococcal Polysaccharide Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for 23-Valent Pneumococcal Polysaccharide Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the 23-Valent Pneumococcal Polysaccharide Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global 23-Valent Pneumococcal Polysaccharide Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for 23-Valent Pneumococcal Polysaccharide Vaccine sales, projected growth trends, production technology, application and end-user industry.


23-Valent Pneumococcal Polysaccharide Vaccine Segment by Company

MSD
Sanofipasteur
CDIBP

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Type

Single Dose Vial
Pre-filled Syringe

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Application

For Children (2-10)
For Person (10-64)
For The Old (Above or equal to 65)

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 23-Valent Pneumococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of 23-Valent Pneumococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 23-Valent Pneumococcal Polysaccharide Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the 23-Valent Pneumococcal Polysaccharide Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of 23-Valent Pneumococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of 23-Valent Pneumococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of 23-Valent Pneumococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, 2020 VS 2024 VS 2031
1.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size Estimates and Forecasts (2020-2031)
1.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Estimates and Forecasts (2020-2031)
1.5 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Dynamics
2.1 23-Valent Pneumococcal Polysaccharide Vaccine Industry Trends
2.2 23-Valent Pneumococcal Polysaccharide Vaccine Industry Drivers
2.3 23-Valent Pneumococcal Polysaccharide Vaccine Industry Opportunities and Challenges
2.4 23-Valent Pneumococcal Polysaccharide Vaccine Industry Restraints
3 23-Valent Pneumococcal Polysaccharide Vaccine Market by Manufacturers
3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Manufacturers (2020-2025)
3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Manufacturers (2020-2025)
3.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Average Sales Price by Manufacturers (2020-2025)
3.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global 23-Valent Pneumococcal Polysaccharide Vaccine Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers, Product Type & Application
3.7 Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market CR5 and HHI
3.8.2 Global Top 5 and 10 23-Valent Pneumococcal Polysaccharide Vaccine Players Market Share by Revenue in 2024
3.8.3 2024 23-Valent Pneumococcal Polysaccharide Vaccine Tier 1, Tier 2, and Tier 3
4 23-Valent Pneumococcal Polysaccharide Vaccine Market by Type
4.1 23-Valent Pneumococcal Polysaccharide Vaccine Type Introduction
4.1.1 Single Dose Vial
4.1.2 Pre-filled Syringe
4.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type
4.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2020-2031)
4.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2031)
4.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type
4.3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2020-2031)
4.3.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2020-2031)
5 23-Valent Pneumococcal Polysaccharide Vaccine Market by Application
5.1 23-Valent Pneumococcal Polysaccharide Vaccine Application Introduction
5.1.1 For Children (2-10)
5.1.2 For Person (10-64)
5.1.3 For The Old (Above or equal to 65)
5.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application
5.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2020-2031)
5.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2020-2031)
5.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application
5.3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2020-2031)
5.3.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2020-2031)
6 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region
6.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2020-2031)
6.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2020-2025)
6.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region
7.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region
7.1.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (2020-2025)
7.1.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (2026-2031)
7.1.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2020-2031)
7.2.2 North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2020-2031)
7.3.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2020-2031)
7.4.2 Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2020-2031)
7.5.2 South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 MSD
8.1.1 MSD Comapny Information
8.1.2 MSD Business Overview
8.1.3 MSD 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 MSD 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
8.1.5 MSD Recent Developments
8.2 Sanofipasteur
8.2.1 Sanofipasteur Comapny Information
8.2.2 Sanofipasteur Business Overview
8.2.3 Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
8.2.5 Sanofipasteur Recent Developments
8.3 CDIBP
8.3.1 CDIBP Comapny Information
8.3.2 CDIBP Business Overview
8.3.3 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
8.3.5 CDIBP Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 23-Valent Pneumococcal Polysaccharide Vaccine Value Chain Analysis
9.1.1 23-Valent Pneumococcal Polysaccharide Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 23-Valent Pneumococcal Polysaccharide Vaccine Production Mode & Process
9.2 23-Valent Pneumococcal Polysaccharide Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 23-Valent Pneumococcal Polysaccharide Vaccine Distributors
9.2.3 23-Valent Pneumococcal Polysaccharide Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings